Integumen (LON:SKIN)

Integumen (LON:SKIN)


Share Price
1.81 p
Change
-0.08 (-4.23 %)
Market Cap
£17.25 m
Proactive Investors - Run By Investors For Investors

Integumen

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products...

EPIC: SKIN
Market: AIM:SKIN
52-week High/Low: 2.58p / 0.35p
Sector: Health Care, Equipment & Services
Market Cap: £17.25 m
Website: integumen.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Integumen


Integumen Snapshot

Chairman's Statement

As Chairman of the Company I am acutely aware of the need for an effective and focused Board that leads the business and builds upon its successes. Strong corporate governance helps underpin the foundations of a solid and successful business. The Board is committed to ensuring good corporate governance, from executive level and throughout the operations of the business. Following the revisions to the AIM Rules for Companies in March 2018 pursuant to which all AIM companies are required to comply with a recognised corporate governance code, the decision has been made by the Company that it will adopt the Quoted Company Alliance Corporate Governance Code 2018. The directors believe that the QCA Code is the most appropriate recognised governance code for the Company.

As Chairman it is my duty to ensure that good standards of governance are delivered and fed throughout the organisation. The Board as a whole looks to instill a culture across the Company, delivering strong values and compliant social and corporate responsibilities.

Since Integumen’s admission to trading on AIM, the integration of multiple isolated and diverse business units covering oral-care, cosmetics, wound care and supported by an animal-free laboratory grown human skin testing technology, has overcome many hurdles. The Board are overseeing the strengthening of the Company and have brought onboard an executive team that are working tirelessly to build on the strong foundations of the underlying business units. During 2017 the Board and management’s primary focus was to deliver a cohesive integration that would strengthen the business and secure the ability to move the Company forward. This was not fully achieved and resulted in the Board decision to reduce investment in non-performing assets early in H1 2018.

A strategic review of the different businesses within the Company was undertaken. As a result, the Board is seeking to divest the Company of under-performing assets or those requiring significant funding in order to leave a strong solid core group of business units that have the potential for accelerated sales growth.

Recent new management and Board appointments have altered the business model and strategy. The vision of the business is to focus on growth of product and services sales of the underlying business units through collaboration, cooperation and development of partnerships with other businesses. These are key to build on the successes and strong foundation of the businesses that are core to the restructured Company. Delivery of our business model is underpinned by our core values of:

  • Integrity to be consistently open, honest, ethical and genuine.
  • Passion and leadership with a commitment to engage and inspire others.
  • Courage to be entrepreneurial enough to reach beyond boundaries.
  • Acceptance and delegation of responsibility.
  • Determination to deliver a proactive customer service


The importance of good governance and working for the benefit of all stakeholders has been at the forefront of the Board. As the Company enters an accelerating commercial phase, building on the early development stages of the past, as Chairman, I will work with the Board to build upon the existing values that are in place and ensure that good corporate governance continues to be present within the organisation and delivered throughout the business, ensuring that we grow with foundations of integrity and strong principles for the benefit of all stakeholders.

Tony Richardson
Non-Executive Chairman

Skin Microbiome

Labskin

Animal-Free Lab-grown, simulated human skin, for testing cosmetic and pharma products for dandruff, acne, fungal and bacterial infection. Learn more.

Innovenn Skin Science

Labskin Certification of products, and training of Lab technicians. Virtual Lab services for cosmetic, skincare and pharma companies. Learn more.

Stoer For Men Cosmetics

Range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of aging. Learn more.

WouldPhase

Visual diagnostic wound dressing that changes colour to indicate infection or improvement of the wound under the dressing. Learn more.

Mico Biomaterials

Omega 3 from Algae

Major health benefits for global  human population explosion. Alternative production to extraction from declining global fish stocks. Learn more.

Bio-Plastic Ingredients

Solution to dumping 8 million tonnes of waste plastic in the oceans each year. Alternative biodegradable plastic solution.

Algzym CBD Technology

Low-cost Solvent-Free commercial scale solution to the production of Omega-3 oils from micro-algae and CBD oils from hemp. 

Cellulac

Commercial License Partners of the Algzym Technology platform for bio-based oils, including Omega 3, CBD and bio-plastic ingredients. Learn more.

We never underestimate the skill and expertise of the management teams of the underlying subsidiaries and partner companies.  Leading those teams are those who have transformed laboratory science to commercial scale multi-national companies.

Gerard J Brandon CEO

Gerard is a seasoned international executive and serial entrepreneur, joining Cellulac as its CEO in May 2012. In 1996 he co-founded, as CEO, Alltracel Pharmaceuticals plc, which completed an IPO on AIM in 2001 and was subsequently acquired in 2008. In 2004 Gerard was appointed Managing Partner for Farmabrand Private Equity. He is an author and Fellow of the Ryan Academy of Entrepreneurs in Dublin.

Camillus Glover COO

Camillus joined Cellulac as CFO in May 2012 and is a Chartered Accountant Institute member since 1985, qualifying with KPMG. He moved from his position as Operations Director at Campbell Bewley Group to be Chief of Operations at Alltracel Pharmaceuticals plc in 2003 and later stayed on after being acquired by Hemcon Medical Technologies as VP Global Business Development, 2009-2012.

Tony Richardson - Chair

Tony is the non-executive chairman of Integumen while also CEO of Venn Life Sciences. He was previously Co-Founder and CEO of Alltracel Pharmaceuticals. A Fellow of the Association of Chartered Certified Accountants and has held key leadership positions in a number of Medical Technology companies and has accumulated considerable transaction experience including IPO, financings and M&A

Tel - +44 (20) 3239 3716

Email - [email protected]

Address

Sand Hutton Applied Innovation Campus,
Sand Hutton, York,
North Yorkshire YO41 1LZ,
United Kingdom

Tel - +44 (20) 3239 3716

Email - [email protected]

Address

Sand Hutton Applied Innovation Campus,
Sand Hutton, York,
North Yorkshire YO41 1LZ,
United Kingdom

Columns Including SKIN

VIEW ALL

Market Reports Including SKIN

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use